{"id":3580,"date":"2014-05-15T11:55:48","date_gmt":"2014-05-15T09:55:48","guid":{"rendered":"https:\/\/celonpharma.com\/?p=3580"},"modified":"2017-11-17T09:35:04","modified_gmt":"2017-11-17T09:35:04","slug":"we-are-going-to-present-our-results-on-esmo-congress","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/","title":{"rendered":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO)"},"content":{"rendered":"<div>\n<p>Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the<a href=\"http:\/\/www.esmo.org\/Conferences\/ESMO-2014-Congress\"> European Society for Medical Oncology (ESMO) Congress<\/a> which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: \u201cPreclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy\u201d.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: \u201cPreclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/\" title=\"ReadWe are presenting the results of our research at the European Society for Medical Oncology (ESMO)\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27],"tags":[],"class_list":["post-3580","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: \u201cPreclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 asRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-15T09:55:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-11-17T09:35:04+00:00\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"We are presenting the results of our research at the European Society for Medical Oncology (ESMO)\",\"datePublished\":\"2014-05-15T09:55:48+00:00\",\"dateModified\":\"2017-11-17T09:35:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/\"},\"wordCount\":77,\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/\",\"name\":\"We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2014-05-15T09:55:48+00:00\",\"dateModified\":\"2017-11-17T09:35:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/we-are-going-to-present-our-results-on-esmo-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"We are presenting the results of our research at the European Society for Medical Oncology (ESMO)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/","og_locale":"en_US","og_type":"article","og_title":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma","og_description":"Celon Pharma S.A. will present the results of its research on innovative kinase inhibitors at the European Society for Medical Oncology (ESMO) Congress which will be held in Madrid on 26-30 September 2014. We encourage participants of the Congress to examine our poster entitled: \u201cPreclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 asRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/","og_site_name":"Celon Pharma","article_published_time":"2014-05-15T09:55:48+00:00","article_modified_time":"2017-11-17T09:35:04+00:00","author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO)","datePublished":"2014-05-15T09:55:48+00:00","dateModified":"2017-11-17T09:35:04+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/"},"wordCount":77,"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/","url":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/","name":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO) - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2014-05-15T09:55:48+00:00","dateModified":"2017-11-17T09:35:04+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/we-are-going-to-present-our-results-on-esmo-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"We are presenting the results of our research at the European Society for Medical Oncology (ESMO)"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/3580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=3580"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/3580\/revisions"}],"predecessor-version":[{"id":12092,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/3580\/revisions\/12092"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=3580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=3580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=3580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}